“I was really pleased to take part in a clinical trial.”
A trial for advanced kidney cancer comparing interleukin 2 alone and interleukin 2 with SRL172
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
SRL172 is a vaccine, which is also a type of biological therapy. It is made from bacteria called mycobacterium vaccae. The bacteria have been killed with heat so they are not harmful. SRL172 helps the immune system recognise and kill cancer cells.
Half the people taking part in this trial had IL-2 alone. The other half had IL-2 and SRL172.
The aim of this trial was to see if the combination of IL-2 and SRL172 is useful for treating advanced kidney cancer. And to see what the side effects are.
Summary of results
This trial showed that SRL172 and IL2 together did not work better than IL-2 alone for advanced kidney cancer.
Unfortunately, the trial stopped recruiting patients earlier than planned because there was a problem with the supply of SRL172. They recruited 37 patients instead of the 66 they had planned to recruit.
The people who had SRL172 and IL-2 actually had fewer side effects than those who had IL-2 alone. Previous studies have shown that the side effects of SRL172 are mild.
It is difficult to draw definite conclusions because the trial was small. The research team feel that further research into the use of SRL172 for kidney cancer would be useful.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Peter Selby
National Institute for Health Research Cancer Research Network (NCRN)